XORTX Financial Statements From 2010 to 2024

XRTX Stock  USD 1.23  0.04  3.36%   
XORTX Therapeutics financial statements provide useful quarterly and yearly information to potential XORTX Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on XORTX Therapeutics financial statements helps investors assess XORTX Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting XORTX Therapeutics' valuation are summarized below:
Market Capitalization
4.3 M
Earnings Share
0.12
We have found one hundred twenty available fundamental gauges for XORTX Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XORTX Therapeutics prevalent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself for the next two years. Market Cap is likely to drop to about 4.1 M in 2024. Enterprise Value is likely to drop to about 851.8 K in 2024
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

XORTX Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM5.5 M3.1 M
Slightly volatile
Other Current Liabilities83.2 K87.6 K241.5 K
Slightly volatile
Total Current Liabilities280.2 K294.9 K805.7 K
Slightly volatile
Accounts Payable186 K195.8 K282.4 K
Slightly volatile
Cash3.6 M3.4 M2.2 M
Slightly volatile
Non Current Assets Total731.9 K1.4 M510.7 K
Slightly volatile
Cash And Short Term Investments3.6 M3.4 M2.2 M
Slightly volatile
Net Receivables35.1 K60.7 K22.3 K
Slightly volatile
Common Stock Shares Outstanding2.1 MM678.8 K
Slightly volatile
Liabilities And Stockholders EquityM5.5 M3.1 M
Slightly volatile
Total Liabilities784.6 K825.9 K1.1 M
Slightly volatile
Total Current Assets4.2 M4.1 M2.6 M
Slightly volatile
Short and Long Term Debt Total10.9 K11.5 K99.3 K
Slightly volatile
Accumulated Other Comprehensive Income3.5 M5.4 M1.9 M
Slightly volatile
Short Term Debt10.9 K11.5 K95.2 K
Slightly volatile
Intangible Assets189 K175.3 K244.3 K
Slightly volatile
Long Term Debt43.5 K49.7 K39.7 K
Slightly volatile
Deferred Long Term Liabilities133.8 K150.5 K163.9 K
Slightly volatile
Short and Long Term Debt43.4 K45.7 K149.1 K
Slightly volatile
Common Stock10.9 M17.1 MM
Slightly volatile
Property Plant Equipment151.6 K144.4 K45.5 K
Slightly volatile
Other Current Assets701 K560.4 K764.9 K
Pretty Stable
Capital Stock13.2 M17.1 M8.8 M
Slightly volatile
Other Liabilities5.4 MM4.8 M
Slightly volatile
Current Deferred Revenue0.80.90.98
Slightly volatile

XORTX Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative996.5 K1.1 M645.8 K
Slightly volatile
Other Operating Expenses2.6 M4.8 M1.6 M
Slightly volatile
Total Operating Expenses2.6 M4.8 M1.6 M
Slightly volatile
Depreciation And Amortization149.1 K142 K38.2 K
Slightly volatile
Research Development1.6 M2.4 M825.4 K
Slightly volatile
Reconciled Depreciation146.7 K139.7 K36.9 K
Slightly volatile
Cost Of Revenue149.1 K142 K40.6 K
Slightly volatile
Interest Income196.1 K255.2 K117.9 K
Slightly volatile
Selling And Marketing Expenses1.1 M1.2 M1.3 M
Slightly volatile

XORTX Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11 M10.4 M2.4 M
Slightly volatile
Capital Expenditures30.8 K47.1 K28.6 K
Pretty Stable
End Period Cash Flow3.6 M3.4 M2.2 M
Slightly volatile
Stock Based Compensation114.9 K121 K211.4 K
Pretty Stable
Depreciation110.4 K105.2 K31.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables348.9 K670.3 K418.7 K
Slightly volatile
Capex To Depreciation0.430.44791.2371
Slightly volatile
Payables Turnover0.760.7250.1513
Slightly volatile
Cash Per Share2.091.73971.714
Slightly volatile
Days Payables Outstanding4785035.5 K
Slightly volatile
Intangibles To Total Assets0.03040.03210.5161
Slightly volatile
Current Ratio14.4913.79542.9345
Slightly volatile
Graham Number8.388.72048.5175
Slightly volatile
Capex Per Share0.02260.02380.1669
Slightly volatile
Average Receivables57 K64.1 K69.8 K
Slightly volatile
Interest Debt Per Share0.00440.00460.4007
Slightly volatile
Debt To Assets0.0510.05370.2572
Slightly volatile
Days Of Payables Outstanding4785035.5 K
Slightly volatile
Ebt Per Ebit0.570.59511.0446
Pretty Stable
Quick Ratio14.4913.79542.9449
Slightly volatile
Cash Ratio12.2711.68952.3388
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.0071.1323
Slightly volatile
Debt Ratio0.0510.05370.2572
Slightly volatile

XORTX Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 M4.3 M21 M
Slightly volatile
Enterprise Value851.8 K896.6 K19.2 M
Slightly volatile

XORTX Fundamental Market Drivers

Forward Price Earnings0.9621
Cash And Short Term Investments3.4 M

XORTX Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.80 
Cost Of Revenue142 K149.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.